These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24590047)

  • 1. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
    Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
    Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
    Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
    J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
    Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
    Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
    Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
    Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
    Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
    Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
    Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
    Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
    Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Melcher A; Vile R
    Mol Ther; 2011 Jan; 19(1):150-8. PubMed ID: 20959810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
    Diaz RM; Galivo F; Kottke T; Wongthida P; Qiao J; Thompson J; Valdes M; Barber G; Vile RG
    Cancer Res; 2007 Mar; 67(6):2840-8. PubMed ID: 17363607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
    Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
    J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
    Braxton CL; Puckett SH; Mizel SB; Lyles DS
    J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.
    Leveille S; Goulet ML; Lichty BD; Hiscott J
    J Virol; 2011 Dec; 85(23):12160-9. PubMed ID: 21917977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
    Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
    Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
    Webb MJ; Sangsuwannukul T; van Vloten J; Evgin L; Kendall B; Tonne J; Thompson J; Metko M; Moore M; Chiriboga Yerovi MP; Olin M; Borgatti A; McNiven M; Monga SPS; Borad MJ; Melcher A; Roberts LR; Vile R
    Nat Commun; 2024 Jun; 15(1):5442. PubMed ID: 38937436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
    Ammayappan A; Peng KW; Russell SJ
    J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
    Gao Y; Bergman I
    J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
    Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R
    Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.